New Drug For Survival In Prostate Cancer
Hormone-resistant prostate cancer than men who have failed chemotherapy for advanced, a new drug called Zytiga (Abiraterone acetate) is used in combination with prednisone steroids can promote the survival rate. According to research published in the New England Journal of Medicine last May.
Based on data from clinical trials that are approved by the FDA Zytiga in April. The drug works by inhibiting the production of hormones testesteron that triggers the growth of cancer cells.
New Drug For Survival In Prostate Cancer
Zytiga prolong survival in this population of patients who have few treatment options after chemotherapy. Similarly, according to senior researcher Dr. Fred Saad, Chief of Urology at the Hospital Notre-Dame de Montreal. Men who use this drug has a median survival time was 14.8 months, compared with 10.9 months for placebo users.
The study included 1195 men with prostate cancer who do not respond to hormonal therapy and chemotherapy has not first. Teams of researchers Daro 147 hospitals randomly gave subjects Zytiga or prednisone plus placebo.
New Drug For Survival In Prostate Cancer
The drug combination was well tolerated by patients even less effects of back pain, fatigue, and spinal cord compression, compared to placebo. Common side effects in those taking Zytiga and prednisone are the white blood cells is lower, water retention, low potassium levels, liver function tests abnornal, high blood pressure and heart problems.
"This study shows that a form of hormone therapy, abiraterone, who works in patients undergoing hormone therapy and standard chemotherapy," said Dr. experts in prostate cancer. Anthony D'Amico, chief of genitourinary radiation oncology at Brigham and Women's Hospital in Boston. These drugs, he says, is an opportunity for patients with late-stage disease to prolong survival, it does not already own.
Hormone-resistant prostate cancer than men who have failed chemotherapy for advanced, a new drug called Zytiga (Abiraterone acetate) is used in combination with prednisone steroids can promote the survival rate. According to research published in the New England Journal of Medicine last May.
Based on data from clinical trials that are approved by the FDA Zytiga in April. The drug works by inhibiting the production of hormones testesteron that triggers the growth of cancer cells.
New Drug For Survival In Prostate Cancer
Zytiga prolong survival in this population of patients who have few treatment options after chemotherapy. Similarly, according to senior researcher Dr. Fred Saad, Chief of Urology at the Hospital Notre-Dame de Montreal. Men who use this drug has a median survival time was 14.8 months, compared with 10.9 months for placebo users.
The study included 1195 men with prostate cancer who do not respond to hormonal therapy and chemotherapy has not first. Teams of researchers Daro 147 hospitals randomly gave subjects Zytiga or prednisone plus placebo.
New Drug For Survival In Prostate Cancer
The drug combination was well tolerated by patients even less effects of back pain, fatigue, and spinal cord compression, compared to placebo. Common side effects in those taking Zytiga and prednisone are the white blood cells is lower, water retention, low potassium levels, liver function tests abnornal, high blood pressure and heart problems.
"This study shows that a form of hormone therapy, abiraterone, who works in patients undergoing hormone therapy and standard chemotherapy," said Dr. experts in prostate cancer. Anthony D'Amico, chief of genitourinary radiation oncology at Brigham and Women's Hospital in Boston. These drugs, he says, is an opportunity for patients with late-stage disease to prolong survival, it does not already own.